Home > Neurology > AAN 2019 > Headache and Migraine > Galcanezumab reduces cluster headache frequency

Galcanezumab reduces cluster headache frequency

Expert
Dr David Dodick, Mayo Clinic, Phoenix, USA
Conference
AAN 2019
In a placebo-controlled trial, the anti-calcitonin gene-related peptide antibody galcanezumab reduced the weekly episodic cluster headache attack frequency from week 1 to 3, and resulted in a greater percentage achieving a reduction in the weekly cluster headache attack frequency at week 3 of at least 50%. The safety profile of galcanezumab was similar to that seen previously in patients with episodic or chronic migraine [1]. Dr David Dodick (Mayo Clinic, Phoenix, USA) stressed that there is underrecognition of cluster headache and a high rate of misdiagnosis that delays the correct diagnosis an average of 5 to 7 years. “Effective acute treatments are underused, and there are no approved medications for prevention.” Presenting results from the double-blind treatment period of this trial, Dr Dodick said participants were randomised to subcutaneous galcanezumab 300 mg (n=49) or placebo (n=57) once monthly. The primary endpoint was the overall mean change fro...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on